Innovheart srl has landed more than $55 million to continue clinical trials of its transcatheter mitral valve replacement (TMVR) system for the treatment of mitral valve disease. The series C equity round was led by Grand Pharmaceutical Group Ltd. (Grand Pharma), together with existing investors Genextra, Panakes Partners and Indaco Venture Partners.

Investors have backed a new precision medicine company targeting clonal hematopoiesis with $40 million. Tensixteen Bio Inc. is on a mission to understand how somatic mutations influence age-related diseases, including cancer. The San Francisco-based startup will use the funds to develop a genomics and clinical platform that can identify patients at high risk of developing disease.

Akili Interactive Inc. is the latest in a growing field of med-tech startups that are merging with special purpose acquisition companies as a backdoor path to an initial public offering. On Wednesday, the digital medicine company reported plans to combine with Social Capital Suvretta Holdings Corp. I in a deal valued at approximately $1 billion.

TORONTO – Hyivy Health Inc. has secured CA$1.1 million (US$888,000) in pre-seed funding to manufacture, test and obtain medical device approval for a women’s pelvic rehabilitation platform and to explore its use for relieving pelvic pain during clinical trials this summer.

Exoskeleton company Wandercraft SAS has landed $45 million in a series C round led by U.S. fund Quadrant Management. The company’s first commercial exoskeleton, Atalante, received CE marking in 2019 and has sold for around $176,000 a piece to European rehabilitation hospitals offering gait re-learning treatment.